Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets.

ABSTRACT:

Background

Triple negative breast cancer (TNBC) is high-risk due to its rapid drug resistance and recurrence, metastasis, and lack of targeted therapy. So far, no molecularly targeted therapeutic agents have been clinically approved for TNBC. It is imperative that we discover new targets for TNBC therapy.

Objectives

A large volume of cancer genomics data are emerging and advancing breast cancer research. We may integrate different types of TNBC genomic data to discover molecular targets for TNBC therapy.

Data sources

We used publicly available TNBC tumor tissue genomic data in the Cancer Genome Atlas database in this study.

Methods

We integratively explored genomic profiles (gene expression, copy number, methylation, microRNA [miRNA], and gene mutation) in TNBC

SUBMITTER: Wang X 

PROVIDER: S-EPMC5265847 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature